Claims for Patent: 12,201,555

Summary for Patent: 12,201,555

Title:	Drug eluting ocular implant
Abstract:	Disclosed herein are drug delivery devices and methods for the treatment of ocular disorders requiring targeted and controlled administration of a drug to an interior portion of the eye for reduction or prevention of symptoms of the disorder. The devices are capable of controlled release of one or more drugs and may also include structures which allows for treatment of increased intraocular pressure by permitting aqueous humor to flow out of the anterior chamber of the eye through the device.
Inventor(s):	David S. Haffner, Kenneth M. Curry, Harold A. Heitzmann, David Applegate
Assignee:	Glaukos Corp
Application Number:	US17/219,102
Patent Claims:	1. A drug delivery ocular implant, comprising: an outer shell shaped to define an interior space, the outer shell having a sidewall, a closed distal end, an open proximal end, and a sidewall connecting the closed distal end and the open proximal end; a drug contained within the interior space; a membrane proximate the open proximal end, the membrane being semi-permeable or permeable to the drug; a cap dimensioned to fit on the open proximal end and comprising compressible regions configured to seal the cap to the outer shell; and an anchor extending along a longitudinal axis of the drug delivery ocular implant and distally from the closed distal end, the anchor configured to affix the implant into an ocular tissue; wherein the cap secures the membrane to the outer shell while providing at least one opening to allow the drug to elute from the implant through the membrane wherein at least a portion of the anchor is configured to extend into the ocular tissue. 2. The drug delivery ocular implant of claim 1, wherein the cap fits on the open proximal end and has at least one central opening. 3. The drug delivery ocular implant of claim 1, wherein the anchor comprises a barb. 4. The drug delivery ocular implant of claim 1, wherein the implant further comprises a shunt comprising an inflow portion and at least one outflow portion. 5. The drug delivery ocular implant of claim 4, wherein the at least one outflow portion of the shunt is disposed near the closed distal end of the implant. 6. The drug delivery ocular implant of claim 4, wherein the open proximal end is for location in an anterior chamber of an eye, and wherein the shunt is for location in a physiologic outflow pathway of the eye. 7. The drug delivery ocular implant of claim 1, wherein the implant is formed from one or more materials including ceramic. 8. The drug delivery ocular implant of claim 1, wherein the implant is formed from one or more materials including titanium. 9. The drug delivery ocular implant of claim 1, wherein the drug is selected from the group consisting of bimatoprost, latanoprost, travoprost, and unoprostone. 10. The drug delivery ocular implant of claim 1, wherein the membrane is permeable to at least one of the drug or an ocular fluid. 11. The drug delivery ocular implant of claim 1, wherein the membrane is elastomeric. 12. A drug delivery ocular implant, comprising: an outer shell shaped to define an interior space, a closed distal end, and an open proximal end, and a sidewall connecting the closed distal end and the open proximal end; a drug contained within the interior space; a cap dimensioned to fit on the open proximal end and comprising an orifice; a permeable or semi-permeable material covering the orifice, the permeable or semi-permeable material being permeable or semi-permeable to the drug; and a retention protrusion extending along a longitudinal axis of the drug delivery ocular implant and distally from the closed distal end, the retention protrusion configured to affix the implant into an ocular tissue wherein at least a portion of the retention protrusion is configured to extend into the ocular tissue. 13. The drug delivery ocular implant of claim 12, wherein the retention protrusion has a shape selected from threads, ridges, pins, barbs, and barbed tips. 14. The drug delivery ocular implant of claim 12, wherein the cap comprises a crimp cap. 15. The drug delivery ocular implant of claim 12, wherein the implant is configured to transport fluid from an anterior chamber to a physiologic outflow space to reduce intraocular pressure. 16. The drug delivery ocular implant of claim 12, wherein the drug is selected from the group consisting of prostaglandin analog agents, beta blocker agents, and anti-proliferative agents. 17. A drug delivery ocular implant, comprising: an outer shell shaped to define an interior space, a closed distal end, an open proximal end, and a sidewall connecting the closed distal end and the open proximal end; a drug contained within the interior space; a permeable or semi-permeable material positioned between an environment exterior to the implant and the drug, the permeable or semi-permeable material being permeable or semi-permeable to the drug; and a retention protrusion extending along a longitudinal axis of the drug delivery ocular implant and distally from the closed distal end, the retention protrusion configured to affix the implant into an ocular tissue wherein at least a portion of the retention protrusion is configured to extend into the ocular tissue. 18. The drug delivery ocular implant of claim 17, wherein the ocular tissue is a portion of a sclera. 19. The drug delivery ocular implant of claim 1, wherein the ocular tissue is a portion of a sclera. 20. The drug delivery ocular implant of claim 12, wherein the ocular tissue is a portion of a sclera.